The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care
Currently available synthetic grafts have contributed to improved outcomes in cardiovascular surgery. However, the implementation of these graft materials at small diameters have demonstrated poor patency, inhibiting their use for coronary artery bypass surgery in adults. Additionally, when applied...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-03-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/9/7/1274 |
| _version_ | 1819162797822443520 |
|---|---|
| author | Yuichi Matsuzaki Kelly John Toshihiro Shoji Toshiharu Shinoka |
| author_facet | Yuichi Matsuzaki Kelly John Toshihiro Shoji Toshiharu Shinoka |
| author_sort | Yuichi Matsuzaki |
| collection | DOAJ |
| description | Currently available synthetic grafts have contributed to improved outcomes in cardiovascular surgery. However, the implementation of these graft materials at small diameters have demonstrated poor patency, inhibiting their use for coronary artery bypass surgery in adults. Additionally, when applied to a pediatric patient population, they are handicapped by their lack of growth ability. Tissue engineered alternatives could possibly address these limitations by producing biocompatible implants with the ability to repair, remodel, grow, and regenerate. A tissue engineered vascular graft (TEVG) generally consists of a scaffold, seeded cells, and the appropriate environmental cues (i.e., growth factors, physical stimulation) to induce tissue formation. This review critically appraises current state-of-the-art techniques for vascular graft production. We additionally examine current graft shortcomings and future prospects, as they relate to cardiovascular surgery, from two major clinical trials. |
| first_indexed | 2024-12-22T17:33:57Z |
| format | Article |
| id | doaj.art-9b78abfeaaef4b46b352499f70aeccfa |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-12-22T17:33:57Z |
| publishDate | 2019-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-9b78abfeaaef4b46b352499f70aeccfa2022-12-21T18:18:33ZengMDPI AGApplied Sciences2076-34172019-03-0197127410.3390/app9071274app9071274The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient CareYuichi Matsuzaki0Kelly John1Toshihiro Shoji2Toshiharu Shinoka3Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACurrently available synthetic grafts have contributed to improved outcomes in cardiovascular surgery. However, the implementation of these graft materials at small diameters have demonstrated poor patency, inhibiting their use for coronary artery bypass surgery in adults. Additionally, when applied to a pediatric patient population, they are handicapped by their lack of growth ability. Tissue engineered alternatives could possibly address these limitations by producing biocompatible implants with the ability to repair, remodel, grow, and regenerate. A tissue engineered vascular graft (TEVG) generally consists of a scaffold, seeded cells, and the appropriate environmental cues (i.e., growth factors, physical stimulation) to induce tissue formation. This review critically appraises current state-of-the-art techniques for vascular graft production. We additionally examine current graft shortcomings and future prospects, as they relate to cardiovascular surgery, from two major clinical trials.https://www.mdpi.com/2076-3417/9/7/1274tissue-engineered vascular graftsbiodegradable materialcongenital heart surgeryarteriovenous shunts |
| spellingShingle | Yuichi Matsuzaki Kelly John Toshihiro Shoji Toshiharu Shinoka The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care Applied Sciences tissue-engineered vascular grafts biodegradable material congenital heart surgery arteriovenous shunts |
| title | The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care |
| title_full | The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care |
| title_fullStr | The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care |
| title_full_unstemmed | The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care |
| title_short | The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care |
| title_sort | evolution of tissue engineered vascular graft technologies from preclinical trials to advancing patient care |
| topic | tissue-engineered vascular grafts biodegradable material congenital heart surgery arteriovenous shunts |
| url | https://www.mdpi.com/2076-3417/9/7/1274 |
| work_keys_str_mv | AT yuichimatsuzaki theevolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT kellyjohn theevolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT toshihiroshoji theevolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT toshiharushinoka theevolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT yuichimatsuzaki evolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT kellyjohn evolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT toshihiroshoji evolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare AT toshiharushinoka evolutionoftissueengineeredvasculargrafttechnologiesfrompreclinicaltrialstoadvancingpatientcare |